CKM Syndrome Stage 1: Redefining Obesity as a Critical Health Risk

A 2026 cardiovascular-kidney-metabolic (CKM) guideline has introduced a new disease continuum that links obesity, diabetes, kidney issues, and heart disease. Stage 1 CKM syndrome is identified not by existing organ failure, but by the presence of dysfunctional adiposity, or unhealthy fat accumulation. This proactive classification marks a shift in preventive medicine, as obesity is now recognized as the metabolically active starting point that triggers systemic inflammation and insulin resistance long before clinical diagnosis of diabetes or heart disease.

India presents a critical case study due to the prevalence of the thin-outside, fat-inside (TOFI) phenomenon, where individuals maintain a lower body mass index but possess high levels of dangerous visceral fat. This biological configuration often leads to early-onset metabolic disorders, fatty liver, and hypertension even in individuals who do not appear obese by traditional Western standards. Rapid urbanization, sedentary lifestyles, and diets high in processed foods are further accelerating the progression of CKM syndrome among millions across the country.

Clinical guidelines emphasize lifestyle modification as the primary intervention for Stage 1 CKM syndrome, focusing on therapeutic weight reduction to restore insulin sensitivity and decrease chronic inflammation. Sustainable dietary changes—specifically increasing fiber, whole grains, and fresh produce—are essential. By addressing dysfunctional adiposity early, medical practitioners aim to prevent the progression toward irreversible chronic kidney and cardiovascular failure, potentially transforming public health outcomes across India.